Novartis Ag

Infinity Discovery, Inc.

Irm LLC

Astex Therapeutics Limited

Infinity Pharmaceuticals, Inc.

Novartis Pharma Gmbh

Lawrence Blas Perez

Zhuoliang Chen

Matthew J LaMarche

Jorge Garcia Fortanet

Rajesh Karki

Martin Sendzik

Mitsunori Kato

Sarah Williams

Christine Hiu-Tung Chen

Troy Douglas Smith

Bakary-Barry Toure

Fan Yang

Alfredo C Castro

Michael Luzzio

Edward Holson

Michael J Grogan

Stacy W Remiszewski

Tao Liu

Daniel A Snyder

Brian T Hopkins

Richard William Versace

Stephane Peluso

Bharat Lagu

Michael Alan Green

Thomas T Tibbitts

Gregg F Keaney

Kenneth Walter Bair

Christopher Thomas Brain

Marta Nevalainen

Bing Yu

Julian Roy Levell

Nathanael Schiander Gray

Miles Stuart Congreve

Feng He

Gang Liu

Steven Howard

Gianni Chessari

Stefan Peukert

Shifeng Pan

Alison Jo-Anne Woolford

Andrew James Woodhead

Yuan Mi

Michael David Shultz

Mark G Palermo

Nathanael S Gray

Wenqi Gao

John William Giraldes

Michael Dore

Sushil Kumar Sharma

Young Shin Cho

Yaping Wang

Nii O Koney

Travis Matthew Stams

Charles W Johannes

Kristopher M Depew

David A Mann

Lidia Cristina Sambucetti

Denise Grunenfelder

Dyuti Majumdar

Peter Ettmayer

Klaus Hinterding

Mark Gabriel Palermo

Naeem Yusuff

Peter Nussbaumer

Miao Dai

Sunkyu Kim

Wei Wang

Claudio Dagostin

Marc O'Reilly

Karen Marie Miller-Moslin

Yipin Lu

Steven Douglas Hiscock

Rishi Kumar Jain

Joseph Kelleher

Patrick James Sarver

Paul Mortenson

Lidia Sambucetti

Sophie Lefebvre

John Lei

Luis Llamas

Michael A Mcewan

Matthew J Lamarche

Wenqui Gao

Andriana Jouk

Federic Zecri

Fan Yi

Kenneth Richad La Montagne

Kenneth Richard La Montagne

Michael Joseph Luzzio

Joseph Iii Kelleher

Edward B Holson

Paul Neil Mortenson

John Grialdes

Ying Fan

Frédéric Zecri

The present invention relates to compounds of formula I:

N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2

Compounds and compositions for inhibiting the activity of SHP2

The present invention relates to compounds of formula I:  in which m, Y, Y, Y, R, R, R, R, R, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

The present invention relates to compounds of formula I: in which p, q, Y, Y, R, R, R, R, R, R, R, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

The present invention relates to compounds of formula I: in which Y, Y, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2. 

The present invention relates to compounds of formula I: 

1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2

The invention is directed to novel pyrrolopyrimidine compounds of formula (1) wherein R, R, R, R-R, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Pyrrolopyrimidine compounds as inhibitors of CDK4/6

The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R, R, R, R-R, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. 

Growing community of inventors

Hopkinton, MA, United States of America

Lawrence Blas Perez